A bioactively modified fatty acid improves survival and impairs metastasis in preclinical models of acute leukemia

Clinical Cancer Research

Volumn 12, Issue 11 I, 2006, Pages 3525-3531

  Iversen, Per O ^a   Sørensen, Dag R ^a   Tronstad, Karl J ^b,c   Gudbrandsen, Oddrun A ^b   Rustan, Arild C ^a   Berge, Rolf K ^b   Drevon, Christian A ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b Institute of Medicine   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; LARD; METALLOPROTEINASE; POLYUNSATURATED FATTY ACID; SULFUR; TETRADECYLTHIOACETIC ACID; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; CANCER INHIBITION; CANCER SURVIVAL; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; ENZYME ACTIVITY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RAT; SUBSTITUTION REACTION; T CELL LEUKEMIA;

ANIMALS; APOPTOSIS; DIET; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; FATTY ACIDS, UNSATURATED; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKEMIA, T-CELL, ACUTE; LEUKEMIC INFILTRATION; MATRIX METALLOPROTEINASES; NEOPLASM METASTASIS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33745202789     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2802     Document Type: Article

References (32)

1. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004;22:2816-25.
2. Farag SS, Ruppert AS, Mrozek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005;23:482-93.
3. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 1997;11:1661-4.
4. Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol 2004;159:259-68.
5. Iversen PO, Drevon CA, Reseland JE. Prevention of leptin binding to its receptor suppresses rat leukemic cell growth by inhibiting angiogenesis. Blood 2002; 100:4123-8.
6. Finstad HS, Kolset SO, Holme JA, et al. Effect of n-3 and n-6 fatty acids on proliferation and differentiation of promyelocytic leukemic HL-60 cells. Blood 1994; 84:3799-809.
7. Finstad HS, Myhrstad MC, Heimli H, et al. Multiplication and death-type of leukemia cell lines exposed to very long-chain polyunsaturated fatty acids. Leukemia 1998;12:921-9.
8. Tronstad KJ, Bruserud O, Berge K, Berge RK. Anti-proliferative effects of a non-β-oxidizable fatty acid, tetradecylthioacetic acid, in native human acute myelogenous leukemia blast cultures. Leukemia 2002;16: 2292-301.
9. Tronstad KJ, Berge K, Berge RK, Bruserud O. Modified fatty acids and their possible therapeutic targets in malignant diseases. Expert Opin Ther Targets 2003; 7:663-77.
10. Tronstad KJ, Gjertsen BT, Krakstad C, et al. Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells. Chem Biol 2003;10: 609-18.
11. Martens AC, van Bekkum DW, Hagenbeek A. The BN acute myelocytic leukemia (BNML) [a rat model for studying human acute myelocytic leukemia (AML)]. Leukemia 1990;4:241-57.
12. Hagenbeek A, Martens AC. High-dose cyclophosphamide treatment of acute myelocytic leukemia. Studies in the BNML rat model. Eur J Cancer Clin Oncol 1982;18:763-9.
13. Roser B, Ford WL. Prolonged lymphocytopenia in the rat. The depletion of blood and thoracic duct lymphocyte populations following injection of emitting colloids into the spleen or lymph nodes. Aust J Exp Biol Med Sci 1972;50:165-84.
14. Dibley M, Dorsch S, Roser B. T cell leukaemia in the rat: the pathophysiology. Pathology 1975;7:219-35.
15. Rehbinder C, Baneux P, Forbes D, et al. FELASA recommendations for the health monitoring of mouse, rat, hamster, gerbil, guinea pig and rabbit experimental units. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Animal Health accepted by the FELASA Board of Management, November 1995. Lab Anim 1996;30:193-208.
16. Iversen PO, Thing-Mortensen B, Nicolaysen G, Benestad HB. Decreased blood flow to rat bone marrow, bone, spleen, and liver in acute leukemia. Leuk Res 1993;17:663-8.
17. Nestvold J, Stokland A, Naper C, Rolstad B. Phenotype and natural killer cell sensitivity of a radiation-induced acute T-cell leukaemia (Roser leukaemia) in PVG rats. Scand J Immunol 2004;60:153-8.
18. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-7.
19. Wergedahl H, Liaset B, Gudbrandsen OA, et al. Fish protein hydrolysate reduces plasma total cholesterol, increases the proportion of HDL cholesterol, and lowers acyl-CoA:cholesterol acyltransferase activity in liver of Zucker rats. J Nutr 2004;134:1320-7.
20. Martens AC, Johnson RJ, Kaizer H, Hagenbeek A. Characteristics of a monoclonal antibody (RM124) against acute myelocytic leukemia cells. Exp Hematol 1984;12:667-71.
21. Thorud HM, Stranda A, Birkeland JA, et al. Enhanced matrix metalloproteinase activity in skeletal muscles of rats with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 2005;289: R389-94.
22. Mortensen BT, Jensen PO, Helledie N, et al. Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol 1998;102:458-64.
23. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 2004;50:87-100.
24. Martens AC, van Bekkum DW, Hagenbeek A. Minimal residual disease in leukemia: studies in an animal model for acute myelocytic leukemia (BNML). Int J Cell Cloning 1990;8:27-38.
25. Abdi-Dezfuli F, Froyland L, Thorsen T, Aakvaag A, Berge RK. Eicosapentaenoic acid and sulphur substituted fatty acid analogues inhibit the proliferation of human breast cancer cells in culture. Breast Cancer Res Treat 1997;45:229-39.
26. Tronstad KJ, Berge K, Dyroy E, Madsen L, Berge RK. Growth reduction in glioma cells after treatment with tetradecylthioacetic acid: changes in fatty acid metabolism and oxidative status. Biochem Pharmacol 2001;61:639-49.
27. Berge K, Tronstad KJ, Flindt EN, et al. Tetradecylthio-acetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis 2001;22:1747-55.
28. Berge RK, Skorve J, Tronstad KJ, Berge K, Gudbrandsen OA, Grav H. Metabolic effects of thia fatty acids. Curr Opin Lipidol 2002;13:295-304.
29. Grav HJ, Tronstad KJ, Gudbrandsen OA, et al. Changed energy state and increased mitochondrial p-oxidation rate in liver of rats associated with lowered proton electrochemical potential and stimulated uncoupling protein 2 (UCP-2) expression: evidence for peroxisome proliferator-activated receptor-α independent induction of UCP-2 expression. J Biol Chem 2003;278:30525-33.
30. Burns CP, Luttenegger DG, Spector AA. Effect of dietary fat saturation on survival of mice with L1210 leukemia. J Natl Cancer Inst 1978;61:513-5.
31. Skrede S, Iversen PO. Enhanced oxygen consumption and fatty acid metabolism in rat bone marrow with acute promyelocytic leukaemia. Leuk Res 1995; 19:463-7.
32. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004;79:935-45.